CD47 aso
1 paper4 findings
- 1 lab in 1 country
- Funders: National Institute of Diabetes and Digestive and Kidney Diseases and 3 more
- 4 of 4 findings with company ties
- Animals1
Outcomes
4Hyperlipidemia
downin mice1
1 study
Hyperlipidemia
downin mice1
CD47 aso decreases hyperlipidemia in mice.
“improved glucose tolerance, insulin sensitivity, and hyperlipidemia”
Animals25 μg/g10 weeksmales
Aging1 Dec 2025
Glucose tolerance
upin mice1
1 study
Glucose tolerance
upin mice1
CD47 aso improves glucose tolerance in mice.
“It also improved glucose tolerance, insulin sensitivity, and hyperlipidemia”
Animals25 μg/g10 weeksmales
Aging1 Dec 2025
Body weight
no changein mice1
1 study
Body weight
no changein mice1
CD47 aso has no effect on body weight in mice.
“without affecting overall body weight in aged mice.”
Animals25 μg/g10 weeksmales
Aging1 Dec 2025
Visceral adiposity
downin mice1
1 study
Visceral adiposity
downin mice1
CD47 aso decreases visceral adiposity in mice.
“CD47ASO treatment selectively reduced visceral adiposity without affecting overall body weight in aged mice.”
Animals25 μg/g10 weeksmales
Aging1 Dec 2025